(Q42572857)

2 November 2017

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy (English)

1 reference

2 November 2017

0 references

10

Judith Klumperman

0 references

Daniel S Chen

object named as

Daniel S Chen

24

0 references

Jeffrey Eastham-Anderson

14

object named as

Jeffrey Eastham-Anderson

1 reference

2 November 2017

Leisa Johnson

1

1 reference

2 November 2017

Mahrukh Huseni

2

1 reference

2 November 2017

Tanya Smyczek

3

1 reference

2 November 2017

Anthony Lima

4

1 reference

2 November 2017

Stacey Yeung

5

1 reference

2 November 2017

Jason H Cheng

6

1 reference

2 November 2017

Rafael Molina

7

1 reference

2 November 2017

David Kan

8

1 reference

2 November 2017

Ann De Mazière

9

1 reference

2 November 2017

Ian Kasman

11

1 reference

2 November 2017

Yin Zhang

12

1 reference

2 November 2017

Mark S Dennis

13

1 reference

2 November 2017

Adrian M Jubb

15

1 reference

2 November 2017

Olivia Hwang

16

1 reference

2 November 2017

Rupal Desai

17

1 reference

2 November 2017

Maike Schmidt

18

1 reference

2 November 2017

Michelle A Nannini

19

1 reference

2 November 2017

Kai H Barck

20

1 reference

2 November 2017

Richard A D Carano

21

1 reference

2 November 2017

William F Forrest

22

1 reference

2 November 2017

Qinghua Song

23

1 reference

2 November 2017

Louie Naumovski

25

1 reference

2 November 2017

Mallika Singh

26

1 reference

2 November 2017

Weilan Ye

27

1 reference

2 November 2017

Priti S Hegde

28

1 reference

2 November 2017

language of work or name

English

0 references

publication date

15 August 2013

1 reference

Journal of Clinical Investigation

2 November 2017

1 reference

2 November 2017

123

1 reference

2 November 2017

9

1 reference

2 November 2017

3997-4009

1 reference

Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes

2 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Expression and clinical significance of EGFL7 in malignant glioma

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Maximum tolerated dose: clinical endpoint for a bygone era?

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Maximizing mouse cancer models

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Contributions of human tumor xenografts to anticancer drug development

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

50 years of preclinical anticancer drug screening: empirical to target-driven approaches.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

VE-statin, an endothelial repressor of smooth muscle cell migration

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

The biology of VEGF and its receptors

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Random-effects models for longitudinal data

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Antiangiogenic therapy--evolving view based on clinical trial results.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Incorporation of bevacizumab in the primary treatment of ovarian cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3754254

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23945239

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23945239

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1172/JCI67892

1 reference

release_okmlni2hnfd2boxhyrxa62nkge

2 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/okmlni2hnfd2boxhyrxa62nkge

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

2 November 2017

PubMed publication ID

23945239

1 reference